Effect of estrogen therapy on vascular perlecan and metalloproteinases 2 and 9 in castrated rats

Climacteric

Volumn 16, Issue 1, 2012, Pages 147-153

  Pompei, L M ^a   Steiner, M L ^a   Theodoro, T R ^a   Souza, P Z ^a   Romanini, A C A ^a   Coulson Thomas, V ^b   Pinhal, M A S ^a   Fernandes, C E ^a  

^a FACULDADE DE MEDICINA DO ABC   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Atherosclerosis; Estrogen; Extracellular Matrix; Perlecan; Proteoglycans

Indexed keywords

ESTRADIOL BENZOATE; GELATINASE A; GELATINASE B; PERLECAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CASTRATION; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; THERAPY EFFECT;

EID: 84872448661     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2012.667173     Document Type: Article

References (20)

1. Toole JF, Chambless LE, Heiss G, Tyroler HA, Paton CC. Prevalence of stroke and transient ischemic attacks in the Atherosclerosis Risk in Communities (ARIC) study. Ann Epidemiol 1993;3: 500-3 (Pubitemid 23339587)
2. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: Framingham study. Ann Intern Med 1976;85: 477-52
3. Rosano GM, Vitale C, Fini M. Cardiovascular aspects of menopausal hormone replacement therapy. Climacteric 2009; 12(Suppl 1): 41-6
4. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166: 357-65 (Pubitemid 43244325)
5. Lopes N, Vasudevans SS, Alvarez RJ, Binkley PF, Goldschmidt PJ. Pathophysiology of plaque instability: insights at the genomic level. Prog Cardiovasc Dis 2002;44: 323-38 (Pubitemid 34535154)
6. Galis ZS, Khtzi JJ. Matrix metalloproteases in vascular remodeling and atherogenesis: the good, the bad and the ugly. Circ Res 2002;90: 251-62 (Pubitemid 34633925)
7. Galis ZS, Sukhova GK, Lark MV, Libby P. Increased expression of matrix metalloproteases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94: 2493-503 (Pubitemid 24379627)
8. Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloprotease-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998;32: 368-72 (Pubitemid 28396484)
9. Planas AM, Sole S, Justicia C. Expression and activation of matrix metalloprotease-2 and -9 in rat brain after focal cerebral ischeamia. Neurobiol Dis 2001;8: 834-46 (Pubitemid 33055599)
10. Wingrove CS, Garr E, Godsland IF, Stevenson JC. 17Betaoestradiol enhances release of matrix metalloprotease-2 from human vascular smooth cells. Biochim Biophys Acta 1998; 1406: 169-74 (Pubitemid 28193070)
11. Lam KK, Cheng PY, Hsiao G, et al. Estrogen deficiency-induced alterations of vascular MMP-2, MT1-MMP, and TIMP-2 in ovariectomized rats. Am J Hypertens 2009;22: 27-34
12. Christodoulakos GE, Panoulis CP, Lambrinoudaki IV, et al. The effect of hormone therapy and raloxifene on serum matrix metalloprotease-2 and -9 in postmenopausal women. Menopause 2004;11: 299-305 (Pubitemid 40362184)
13. Wakatsuki A, Ikenoue N, Shinohara K, Watanabe K, Fukaya T. Different effects of oral and transdermal estrogen replacement therapy on matrix metalloprotease and their inhibitor in postmenopausal women. Arterioscler Thromb Vasc Biol 2003;23: 1948-9 (Pubitemid 37254889)
14. Kruegel J, Miosge N. Basement membrane components are key players in specialized extracellular matrices. Cell Mol Life Sci 2010;67: 2879-95
15. Zanger D, Yang BK, Ardans J, et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol 2000;36: 1797-802
16. Natoli AK, Medley TL, Ahimastos AA, et al. Sex steroids modulate human aortic smooth muscle cell matrix protein deposition and matrix metalloprotease expression. Hypertension 2005;46: 1129-34 (Pubitemid 41533015)
17. Marfella R, Di Filippo C, Portoghese M, Ferraraccio F. Proteasome activity as a target of hormone replacement therapy-dependent plaque stabilization in postmenopausal women. Hypertension 2008;51: 1135-41 (Pubitemid 351398963)
18. Farach-Carson MC, Carson DD. Perlecan - a multifunctional extracellular proteoglycan scaffold. Glycobiology 2007;17: 897-905 (Pubitemid 47423879)
19. Tannock LR, King VL. Proteoglycan mediated lipoprotein retention: a mechanism of diabetic atherosclerosis. Rev Endocr Metab Disord 2008;9: 289-300
20. Iozzo RV, San Antonio JD. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest 2001;108: 349-55 (Pubitemid 32730778)